Dimethyl fumarate
| Code | Size | Price |
|---|
| AG-CR1-3701-G001 | 1 g | £25.00 |
Quantity:
| AG-CR1-3701-G005 | 5 g | £32.00 |
Quantity:
| AG-CR1-3701-G025 | 25 g | £40.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
+4°C
Documents
Further Information
Alternate Names/Synonyms:
DMF; DMFu; Fumaric Acid Dimethyl Ester; BG00012; NSC25942; NSC167432; trans-Butenedioic acid dimethyl ester
Appearance:
White to off-white powder.
CAS:
624-49-7
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS05,GHS07
Handling Advice:
Keep cool and dry.
Hazards:
H312, H315, H317, H318
InChi:
InChI=1S/C6H8O4/c1-9-5(7)3-4-6(8)10-2/h3-4H,1-2H3/b4-3+
InChiKey:
LDCRTTXIJACKKU-ONEGZZNKSA-N
Long Description:
Chemical. CAS: 624-49-7. Formula: C6H8O4. MW: 144.1. Immunomodulatory and anti-inflammatory agent used in patients with relapsing-remitting multiple sclerosis (MS) and psoriasis. Causes an immune switch characterized by induction of anti-inflammatory/regulatory innate and adaptive immune cell populations such as regulatory T cells (Tregs) and inhibition or apoptosis of pro-inflammatory cells, such as T helper 1 (Th1) and Th17 subsets. Blocks immune cell activation through inhibition of glycolysis via post-transcriptional modification (succination) of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in vitro and in vivo and is therefore a useful agent for immunometabolism research. GAPDH catalyzes the conversion of glyceraldehyde 3-phosphate to 1,3-bisphosphoglycerate during glycolysis, an essential metabolic pathway where glucose is converted to pyruvate, to fuel the TCA cycle and oxidative phosphorylation (OXPHOS) for the production of adenosine triphosphate (ATP) as an energy source. GAPDH was previously reported to be succinated on the cysteine-152 in the active site, a modification that leads to the irreversible inactivation of its enzymatic activity. Immunomodulatory effects have been shown on both tissue and immune cells. Possible targets include the engagement of antioxidant responses through activation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), inhibition of nuclear factor kappa-light-chain enhancer of activated B cells (NF-kB) and engagement with a putative receptor called HCA2. Suppresses NLRP3 inflammasome activation through Nrf2 activation. Anticancer agent. Angiogenesis inhibitor in vitro and in vivo. Blocks NF-kappaB activity in multiple breast cancer cell lines and abrogates NF-kappaB-dependent mammosphere formation, inhibits cell proliferation and significantly impairs xenograft tumor growth. Exerts neuroprotective effects in vivo in experimental autoimmune encephalomyelitis. Has antimicrobial and antifungal activity. Derivative of the TCA cycle intermediate fumarate. Rapidly interacts in a Michael addition reaction with glutathione or is metabolized to monomethyl fumarate.
MDL:
MFCD00064438
Molecular Formula:
C6H8O4
Molecular Weight:
144.1
Package Type:
Vial
Precautions:
P305+P351+P338, P302+P352, P310
Product Description:
Immunomodulatory and anti-inflammatory agent used in patients with relapsing-remitting multiple sclerosis (MS) and psoriasis. Causes an immune switch characterized by induction of anti-inflammatory/regulatory innate and adaptive immune cell populations such as regulatory T cells (Tregs) and inhibition or apoptosis of pro-inflammatory cells, such as T helper 1 (Th1) and Th17 subsets. Blocks immune cell activation through inhibition of glycolysis via post-transcriptional modification (succination) of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in vitro and in vivo and is therefore a useful agent for immunometabolism research. GAPDH catalyzes the conversion of glyceraldehyde 3-phosphate to 1,3-bisphosphoglycerate during glycolysis, an essential metabolic pathway where glucose is converted to pyruvate, to fuel the TCA cycle and oxidative phosphorylation (OXPHOS) for the production of adenosine triphosphate (ATP) as an energy source. GAPDH was previously reported to be succinated on the cysteine-152 in the active site, a modification that leads to the irreversible inactivation of its enzymatic activity. Immunomodulatory effects have been shown on both tissue and immune cells. Possible targets include the engagement of antioxidant responses through activation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), inhibition of nuclear factor kappa-light-chain enhancer of activated B cells (NF-kB) and engagement with a putative receptor called HCA2. Suppresses NLRP3 inflammasome activation through Nrf2 activation. Dimethyl fumarate (DMF) affects inflammatory responses by inhibiting cleavage of Gasdermin D and consequently pyroptotic cell death, by succination of a critical cysteine of Gasdermin D (GSDMD) to prevent its interaction with caspases, its oligomerization to form membrane pore and its capacity to induce cell death. Anticancer agent. Angiogenesis inhibitor in vitro and in vivo. Blocks NF-kappaB activity in multiple breast cancer cell lines and abrogates NF-kappaB-dependent mammosphere formation, inhibits cell proliferation and significantly impairs xenograft tumor growth. Exerts neuroprotective effects in vivo in experimental autoimmune encephalomyelitis. Has antimicrobial and antifungal activity. Derivative of the TCA cycle intermediate fumarate. Rapidly interacts in a Michael addition reaction with glutathione or is metabolized to monomethyl fumarate.
Purity:
>95%
Signal word:
Danger
SMILES:
O=C(/C=C/C(OC)=O)OC
Solubility Chemicals:
Soluble in DMSO (10mg/ml), ethanol (5mg/ml) or DMF (10mg/ml). Sparingly soluble in aqueous buffers.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Inhibition of Escherichia coli by dimethyl fumarate: H.H. Wang, et al.; Int. J. Food Microbiol. 65, 125 (2001) | Dimethyl fumarate, a small molecule drug for psoriasis, inhibits Nuclear Factor-kappaB and reduces myocardial infarct size in rats: S. Meili-Butz, et al.; Eur. J. Pharmacol. 586, 251 (2008) | Dimethylfumarate inhibits angiogenesis in vitro and in vivo: a possible role for its antipsoriatic effect?: M. Garcia-Caballero, et al.; J. Invest. Dermatol. 131, 1347 (2011) | Dimethyl fumarate: a Janus-faced substance? F. Kees; Expert Opin. Pharmacother. 14, 1559 (2013) (Review) | Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy: A.J. Gill & D.L. Kolson; Crit. Rev. Immunol. 33, 307 (2013) (Review) | Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis: J.V. Venci & M.A. Gandhi; Ann. Pharmacother. 47, 1697 (2013) (Review) | Dimethyl fumarate inhibits the expression and function of hypoxia-inducible factor-1alpha (HIF-1alpha): G. Zhao, et al.; BBRC 448, 303 (2014) | Dimethyl fumarate induces apoptosis of hematopoietic tumor cells via inhibition of NF-kappaB nuclear translocation and down-regulation of Bcl-xL and XIAP: M. Tsubaki, et al.; Biomed. Pharmacother. 68, 999 (2014) | Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway: X. Xie, et al.; Br. J. Pharmacol. 172, 3929 (2015) | Dimethyl fumarate ameliorates dextran sulfate sodium-induced murine experimental colitis by activating Nrf2 and suppressing NLRP3 inflammasome activation: X. Liu, et al.; Biochem. Pharmacol. 112, 37 (2016) | Dimethyl Fumarate Controls the NRF2/DJ-1 Axis in Cancer Cells: Therapeutic Applications: N.E. Saidu, et al.; Mol. Cancer Ther. 16, 529 (2017) | Dimethyl Fumarate Induces Glutathione Recycling by Upregulation of Glutathione Reductase: C. Hoffmann, et al.; Oxid. Med. Cell Longev. 2017, 6093903 (2017) | Targeting Thioredoxin-1 by dimethyl fumarate induces ripoptosome-mediated cell death: A. Schroeder, et al.; Sci. Rep. 7, 43168 (2017) | Opposing effects of Nrf2 and Nrf2-activating compounds on the NLRP3 inflammasome independent of Nrf2-mediated gene expression: M. Garstkiewicz, et al.; Eur. J. Immunol. 47, 806 (2017) | Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity: M.D. Kornberg, et al.; Science 360, 449 (2018) | Dimethyl fumarate downregulates the immune response through the HCA2/GPR109A pathway: Implications for the treatment of multiple sclerosis: F. von Glehn, et al.; Mult. Scler. Relat. Disord. 23, 46 (2018) (Review) | Dimethyl fumarate: targeting glycolysis to treat MS: S. Angiari & A. O'Neill; Cell Res. 28, 613 (2018) (Comment) | Succination inactivates gasdermin D and blocks pyroptosis: F. Humphries, et al.; Science 369, 1633 (2020)
Related Products
| Product Name | Product Code | Supplier | 2-Deoxy-D-glucose | AG-CR1-3681 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3-Bromopyruvic acid | AG-CR1-3682 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||